Home › Funds › Nicholas Investment Partners, LP › BBIO

Nicholas Investment Partners, LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Nicholas Investment Partners, LP reported holding 6,000,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$9.0M, representing 0.68% of its reported portfolio and ranking #48 among its reported holdings. Nicholas Investment Partners, LP has disclosed BBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)6.00M sh
Reported value held$9.04M
Portfolio Weight0.68%
First reportedQ3 2024
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Nicholas Investment Partners, LP's BBIO position evolved

Nicholas Investment Partners, LP first disclosed a stake in BBIO in Q3 2024 at 35,644 shares (US$907K). The position peaked in Q4 2025 at 284,682 shares, worth US$21.8M. Across 9 filings, Nicholas Investment Partners, LP increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 6,000,000 shares valued at US$9.0M. Notable position changes include a 178% increase in Q1 2025 (shares rose 25% over the following quarter), a 70% increase in Q3 2025 (shares rose 47% over the following quarter), a 2008% increase in Q1 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 35.64K $907.50K New
Q4 2024 59.89K $1.64M Add
Q1 2025 166.66K $5.76M Add
Q2 2025 159.50K $6.89M Reduce
Q3 2025 271.63K $14.11M Add
Q4 2025 284.68K $21.78M Add
Q1 2026 6.00M $10.17M Add
Q2 2026 6.00M $10.09M Hold
Q3 2026 6.00M $9.04M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 42 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Nicholas Investment Partners, LP held BBIO?

Nicholas Investment Partners, LP has disclosed BBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Nicholas Investment Partners, LP's current position in BBIO?

As of Q3 2026, Nicholas Investment Partners, LP holds 6.00M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $9.04M, representing 0.68% of its reported portfolio and ranking #48.

Has Nicholas Investment Partners, LP been buying or selling BBIO?

In the latest 13F filing (Q3 2026), Nicholas Investment Partners, LP held unchanged its position in BBIO. The position peaked in Q4 2025 at 284.68K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.